Angiotensin-Converting Enzyme Inhibitors
"Angiotensin-Converting Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.
| Descriptor ID |
D000806
|
| MeSH Number(s) |
D27.505.519.389.745.085
|
| Concept/Terms |
Angiotensin-Converting Enzyme Inhibitors- Angiotensin-Converting Enzyme Inhibitors
- Angiotensin Converting Enzyme Inhibitors
- Inhibitors, Kininase II
- Kininase II Antagonists
- Kininase II Inhibitors
- Angiotensin I-Converting Enzyme Inhibitors
- Angiotensin I Converting Enzyme Inhibitors
- Antagonists, Angiotensin-Converting Enzyme
- Antagonists, Angiotensin Converting Enzyme
- Antagonists, Kininase II
- Inhibitors, ACE
- ACE Inhibitors
- Inhibitors, Angiotensin-Converting Enzyme
- Enzyme Inhibitors, Angiotensin-Converting
- Inhibitors, Angiotensin Converting Enzyme
- Angiotensin-Converting Enzyme Antagonists
- Angiotensin Converting Enzyme Antagonists
- Enzyme Antagonists, Angiotensin-Converting
|
Below are MeSH descriptors whose meaning is more general than "Angiotensin-Converting Enzyme Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Angiotensin-Converting Enzyme Inhibitors".
This graph shows the total number of publications written about "Angiotensin-Converting Enzyme Inhibitors" by people in this website by year, and whether "Angiotensin-Converting Enzyme Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 3 | 2 | 5 |
| 1994 | 1 | 4 | 5 |
| 1995 | 2 | 1 | 3 |
| 1996 | 3 | 2 | 5 |
| 1997 | 5 | 7 | 12 |
| 1998 | 2 | 3 | 5 |
| 1999 | 4 | 1 | 5 |
| 2000 | 4 | 4 | 8 |
| 2001 | 4 | 1 | 5 |
| 2002 | 5 | 4 | 9 |
| 2003 | 4 | 7 | 11 |
| 2004 | 6 | 8 | 14 |
| 2005 | 4 | 6 | 10 |
| 2006 | 1 | 6 | 7 |
| 2007 | 7 | 7 | 14 |
| 2008 | 9 | 11 | 20 |
| 2009 | 5 | 5 | 10 |
| 2010 | 6 | 6 | 12 |
| 2011 | 1 | 3 | 4 |
| 2012 | 3 | 2 | 5 |
| 2013 | 3 | 3 | 6 |
| 2014 | 4 | 4 | 8 |
| 2015 | 4 | 6 | 10 |
| 2016 | 3 | 3 | 6 |
| 2017 | 0 | 5 | 5 |
| 2018 | 3 | 3 | 6 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 4 | 5 |
| 2021 | 3 | 1 | 4 |
| 2022 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Angiotensin-Converting Enzyme Inhibitors" by people in Profiles.
-
The histological spectrum of ARB-induced gastritis. Histopathology. 2022 Nov; 81(5):653-660.
-
Outcomes of guideline-based medical therapy in patients with acute heart failure and reduced left ventricular ejection fraction: Observations from the Gulf acute heart failure registry (Gulf CARE). Medicine (Baltimore). 2022 Jun 10; 101(23):e29452.
-
Effect of Antihypertensives by Class on Cerebral Small Vessel Disease: A Post Hoc Analysis of SPRINT-MIND. Stroke. 2022 08; 53(8):2435-2440.
-
Self-Reported Antihypertensive Medication Class and Temporal Relationship to Treatment Guidelines. Hypertension. 2022 02; 79(2):338-348.
-
Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects. Nat Rev Nephrol. 2022 01; 18(1):56-70.
-
Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension. Am J Hypertens. 2021 05 22; 34(5):531-539.
-
Outcomes of Hospitalized COVID-19 Patients Receiving Renin Angiotensin System Blockers and Calcium Channel Blockers. Am J Nephrol. 2021; 52(3):250-260.
-
A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19. PLoS Biol. 2020 11; 18(11):e3000970.
-
Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. JACC Heart Fail. 2020 10; 8(10):834-843.
-
Neurohormonal Blockade During Left Ventricular Assist Device Support. ASAIO J. 2020 08; 66(8):881-885.